Stockscreener 앱 받기
1.49
0.00%
0.00
시간 외 거래:
1.50
0.01
+0.67%
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Can Allogene Therapeutics Inc. stock outperform in 2025 bull marketOptions Play & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - ulpravda.ru
How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - ulpravda.ru
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India
Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - MarketScreener
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - Yahoo Finance
Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - ulpravda.ru
UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus
UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa
UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
Why Allogene Therapeutics Inc. stock is favored by pension fundsTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда
Allogene Therapeutics Earnings Notes - Trefis
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus
Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada
Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India
Allogene Therapeutics Reaffirms Control of Cemacabtagene Ansegedleucel Following Arbitration Ruling - Quiver Quantitative
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - sahmcapital.com
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewswire
Allogene (NASDAQ: ALLO) arbitration clears path to global cema-cel rights deal - Stock Titan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
December 2025 Penny Stocks Worth Watching - simplywall.st
Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union
Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser
Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union
Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union
Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
0.80%
4.56%
자본화:
|
볼륨(24시간):